Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29572859 | 1.00 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2CASP7TP53 | |
| Anthraquinone SCHEMBL4660434 | 0.88 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2CASP7TP53 | |
| SCHEMBL30704451 | 0.85 | SMN1; SMN2 (0.73) | RAB9ANPC1SMN1; SMN2CASP7TP53 | |
| SCHEMBL30646327 | 0.85 | SMN1; SMN2 (0.73) | RAB9ANPC1SMN1; SMN2CASP7TP53 | |
| SCHEMBL824357 | 0.85 | SMN1; SMN2 (0.73) | RAB9ANPC1SMN1; SMN2CASP7TP53 | |
| SCHEMBL824397 | 0.85 | SMN1; SMN2 (0.73) | RAB9ANPC1SMN1; SMN2CASP7TP53 | |
| SCHEMBL278691 | 0.84 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2CASP7TP53 | |
| SCHEMBL9436882 | 0.84 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2CASP7TP53 | |
| SCHEMBL8832011 | 0.84 | NPC1 (0.71) | RAB9ANPC1SMN1; SMN2CASP7TP53 | |
| SCHEMBL8832035 | 0.84 | NPC1 (0.71) | RAB9ANPC1SMN1; SMN2CASP7TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | claimed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | claimed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | claimed |
| CN-110540541-A | 6H-indolo [2,3-b ] quinoxaline compound and preparation method and application thereof | UNIV GUANGXI NORMAL | 2019-12-06 | — | — | CN | claimed |
| US-20160106743-A1 | TOPOISOMERASE II POISONS AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF ROCHESTER (US) | 2016-04-21 | — | — | US | claimed |
| US-8999522-B2 | 6H-indolo[2,3-b]quinoxaline derivatives and organic light emitting diode using the same | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-04-07 | — | — | US | claimed |
| US-20110303901-A1 | 6H-INDOLO[2,3-b]QUINOXALINE DERIVATIVES AND ORGANIC LIGHT EMITTING DIODE USING THE SAME | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | claimed |
| US-5597921-A | ANTITUMOR AGENTS, TREATMENT OF LEUKEMIA | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1997-01-28 | — | — | US | claimed |
| EP-0695754-A1 | INDOLO 2,3-b]QUINOXALINE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1996-02-07 | — | — | EP | claimed |
| JP-57119905-A | — | — | None | — | — | JP | disclosed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| EP-4543856-A1 | BENZOCARBAZOLE DERIVATIVES AS INHIBITORS OF DRP1 | Asha Therapeutics LLC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250011590-A1 | OPTICAL FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2025-01-09 | — | — | US | disclosed |
| US-4916124-A | Indoloquinoxalines with substituents in 6-position containing cyclic groups as antiviral agents | Lundblad, Lief (SE) | 1990-04-10 | — | — | US | disclosed |
| EP-0238459-A1 | Substituted indoloquinoxalines | Lundblad, Leif (SE) | 1987-09-23 | — | — | EP | disclosed |
| EP-0231159-A1 | Indoloquinoxalines with substituents in 6-position containing cyclic groups | Lundblad, Leif (SE) | 1987-08-05 | — | — | EP | disclosed |
| WO-1987004436-A1 | SUBSTITUTED INDOLOQUINOXALINES | LUNDBLAD, LEIF (SE) | 1987-07-30 | — | — | WO | disclosed |
| WO-1987004437-A1 | INDOLOQUINOXALINES WITH SUBSTITUENTS IN 6-POSITION CONTAINING CYCLIC GROUPS | LUNDBLAD, LEIF (SE) | 1987-07-30 | — | — | WO | disclosed |
| JP-S57119905-A | PREPARATION OF 6-VINYL INDOLO(2,3-B)QUINOXALINE POLYMER | RICOH CO LTD | 1982-07-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | RAB9A 1478/4885NPC1 4647/4885SMN1; SMN2 621/4885 |
| US-20110303901-A1 | 6H-INDOLO[2,3-b]QUINOXALINE DERIVATIVES AND ORGANIC LIGHT EMITTING DIODE USING THE SAME | IDO1, IPO9, IDO2 | RAB9A 135/4885NPC1 1974/4885SMN1; SMN2 4750/4885 |
| US-20160106743-A1 | TOPOISOMERASE II POISONS AND METHODS OF MAKING AND USING SAME | TOP2A, TOP2B, TOP1 | RAB9A 3488/4885NPC1 2563/4885SMN1; SMN2 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.